SPARTAN Study Reports Positive Interim Outcomes
Recent clinical research highlights significant advancements in patient outcomes following lateral-oblique sacroiliac (SI) joint fusion with the innovative TransLoc 3D™ System. The SPARTAN Study, a multicenter study, aimed to evaluate these outcomes based on patient-reported experiences. The interim results from this study display encouraging data, setting a strong foundation for the continued exploration of this surgical approach.
Understanding the SPARTAN Study
The SPARTAN Study showcases a systematic approach, collecting patient data from various centers, which enriches the findings considerably. At the interim analysis, 114 patients underwent the procedure, with 72 patients successfully completing their 6-month follow-up. Validated assessments measured pain and functional improvements both at the beginning and six months after surgery.
Key Outcomes of the Interim Analysis
The data revealed that patients experienced significant improvements right from the first three months post-procedure. By the six-month mark, an impressive 91.67% of participants noted improvements in pain and functional capabilities. Moreover, about 70.83% of the patients achieved at least a 50% reduction in their pain levels, averaging a notable 59.90% reduction as documented by the Numerical Rating Scale (NRS). These results signify substantial relief in patients' lives including enhanced functional mobility reflected by a 49.01% average improvement on the Oswestry Disability Index (ODI).
Insights from Leadership
Bob Compton, the visionary Founder and CEO of CornerLoc™, commented on the significance of these findings, stating, "The publication of these interim SPARTAN results represents an important step in building high-quality clinical evidence around the TransLoc 3D™ procedure and the lateral-oblique approach for SI joint fusion. The interim findings support a favorable safety profile alongside meaningful improvements in pain and function associated with the lateral-oblique approach." His insights underline the importance of this method as a viable solution for patients suffering from SI joint pain.
The Journey Ahead for the SPARTAN Study
As the study progresses, it will continue to monitor patients for an entire year to further solidify the safety and efficacy of this treatment. The ongoing nature of this research reflects CornerLoc™'s commitment to enhancing surgical solutions and fostering advancements in patient care.
Further Details Available
The complete results of the 6-month interim analysis, encompassing detailed methodologies and varying outcome measures, portray a comprehensive overview of the study's contributions to the medical community.
About CornerLoc™
CornerLoc™ specializes in creating surgical solutions aimed at effectively treating SI joint fusion. Their flagship product, the TransLoc 3D™ SI Joint Fusion System, offers flexible options tailored to meet the diverse needs of patients and preferences of physicians. This commitment to innovation positions CornerLoc™ as a leader in the medical industry.
Frequently Asked Questions
What is the SPARTAN Study?
The SPARTAN Study is a multicenter clinical research project assessing the outcomes of lateral-oblique SI joint fusion using the TransLoc 3D™ System.
What were the key findings from the interim analysis?
The interim analysis revealed significant patient improvements in pain and functionality, with 91.67% of patients reporting benefits at the 6-month mark.
How many patients were involved in the SPARTAN Study?
A total of 114 patients participated in the SPARTAN Study as of the interim data cutoff date.
What does the TransLoc 3D™ System offer?
The TransLoc 3D™ System provides an innovative approach to SI joint fusion, accommodating various surgical techniques based on individual patient needs.
What is the next phase of the SPARTAN Study?
The SPARTAN Study will continue for a full year, aiming to evaluate ongoing safety and clinical outcomes for the patients involved.
